The overall goal of this project is to define gene defects that cause ALS-FTD, starting with a subset of families in whom this disease has been mapped to a locus on chromosome 9. The study will test the following hypotheses: 1 ) that a single gene defect, transmitted as a dominant trait, initiates cell death in two distinctive populations of neurons, and 2) this condition is accompanied by oxidative pathology.
The aims of the study are to collect and clinically characterize ALS-FTD families; to use genetic-linkage analysis to determine if new families are genetically homogeneous (linked to the same locus); to develop a physical map of the ALS-FTD loci to identify candidate genes; to screen candidates for mutations; and, when an ALS-FTD gene is identified, screen for this gene in a large series of individuals with ALS or dementia alone. A parallel objective is to assess levels of oxidative cytopathology in the brains and fluids of these patients, testing the hypothesis that, as in many other neurodegenerative disorders, brain tissue of patients with ALS-FTD will show oxidative pathology. To date, no causative gene defects have been identified in ALS-FTD, nor have tissues from these patients been systematically analyzed for markers of excitatory and oxidative pathology. It is the long-term goal of this study that insights into novel mechanisms of cellular death which are prominent in two functionally distinct sets of neurons may illuminate the pathogenesis of other types of motor neuron disease and other forms of dementia and, ultimately, open new avenues for treating these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG012992-08
Application #
6660873
Study Section
Project Start
2002-09-30
Project End
2003-08-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Zhang, Ke; Donnelly, Christopher J; Haeusler, Aaron R et al. (2015) The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525:56-61
Matthews, Christopher C; Fishman, Paul S; Wittenberg, George F (2014) Tetanus toxin reduces local and descending regulation of the H-reflex. Muscle Nerve 49:495-501
van Zundert, Brigitte; Peuscher, Marieke H; Hynynen, Meri et al. (2008) Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci 28:10864-74
Ranganathan, Srikanth; Williams, Eric; Ganchev, Philip et al. (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95:1461-71
Ryu, Hoon; Smith, Karen; Camelo, Sandra I et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93:1087-98
Maxwell, Michele M; Pasinelli, Piera; Kazantsev, Aleksey G et al. (2004) RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci U S A 101:3178-83
Ulug, Aziz M; Grunewald, Thomas; Lin, Michael T et al. (2004) Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. J Magn Reson Imaging 19:34-9
Klivenyi, Peter; Kiaei, Mahmoud; Gardian, Gabrielle et al. (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88:576-82
Pasinelli, Piera; Belford, Mary Elizabeth; Lennon, Niall et al. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43:19-30
Klivenyi, Peter; Calingasan, Noel Y; Starkov, Anatoly et al. (2004) Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 15:610-7

Showing the most recent 10 out of 89 publications